The Conversation: ScyNexis ($SCYX) CFO Eric Francois

by DrKSSMDPhD | April 22, 2017 2:49 pm

This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.

Source URL: https://sgumdev.stockgumshoe.com/2017/04/the-conversation-scynexis-scyx-cfo-eric-francois/


207 Comments
Inline Feedbacks
View all comments

Notice: Undefined variable: karmaOutput in /home/sgumdev/public_html/wp-content/themes/sgum_2016/functions.php on line 3288
๐Ÿ‘ 47658
khol999
khol999
5 years ago

$AUPH Some Upcoming Related:
-May 2 – Bloom Burton Health Care Conference
-May 10 – World Lupus Day
-May 11 – Earning Report
-May 15 – Tute filing of ownership

Just some fyi…

๐Ÿ‘ 74
SoGiAm
5 years ago
Reply to  khol999

$AUPH long โ€“ This is the exact type of post WEโ€™d luv to see posted to OUR biotech/medical CATALYST calendar thread; Thank you khol999!: Cross-posted to: https://www.sgumdev.stockgumshoe.com/2015/04/microblog-biotechmedical-catalyst-calender/comment-page-6/#comment-4931049

๐Ÿ‘ 11466
LostOkie
LostOkie
5 years ago

$APTO long Dr. KSS, I just saw this on SA The SVP/ chief business officer resigns! Right outa the blue aint it!? What does this change for you? anything?

https://seekingalpha.com/news/3253573-aptose-bios-business-chief-bids-adieu

Add a Topic
3932
๐Ÿ‘ 306
batanaso101
batanaso101
5 years ago
Reply to  LostOkie

$APTO long
This is old news – from a month ago.

๐Ÿ‘ 24
LostOkie
LostOkie
5 years ago
Reply to  LostOkie

WOOPS! Sorry folks, Looking again I see that was March, not April. Sorry if I gave anyone stroke!!

๐Ÿ‘ 306
SoGiAm
5 years ago
Reply to  LostOkie

$APTO

๐Ÿ‘ 11466
๐Ÿ‘ 47658
chris27
chris27
5 years ago
Reply to  DrKSSMDPhD

$ABVX.PA/$AAVXF(OTC):
For HIV ABX-464 the MoA is just similar to many other HIV drug, it prevents viral replication. Basically that’s a company targerting infectious diseases,
but recently they diversified into IBD with that same agent ABX-464,
they also have a NKT cell pltform they want to out-license (partnership).
It’s a company from the Truffle Fund pool.
ABX-464 effect on viral rebound study earnings on the 1st>data on May 2nd, I am led to believe.

Disclosure: $AAVXF NP, although I am intrigued by this company’s pipeline.

Add a Topic
5153
Add a Topic
5153
Add a Topic
285
๐Ÿ‘ 3
adadfarm
adadfarm
5 years ago
Reply to  chris27

$AAVXF, long- the following was noted in the company’s 3/17/17 PR: “A second phase IIa study(ABX464004), this time a treatment interruption study, was started in June
2016 in Spain, Belgium and France to explore the long term therapeutic effect of ABX 464 when used in
association with other antivirals. [. . . .] The first results will be
come available at the end of April.” – Curt

๐Ÿ‘ 942
adadfarm
adadfarm
5 years ago
Reply to  DrKSSMDPhD

$APTO – Thanks, Doc! Tripled my position today. – Curt

๐Ÿ‘ 942
Patrick Peterson
Patrick Peterson
5 years ago

$BLPH
Bellerophon back above $1.60 on high volume. Stock has really bounced back since Dr. KSS told us only 2 weeks ago the sell off was unwarranted and due to bad judgment by management. Since then, there was a positive story out of the Cleveland Clinic and the stock has been heading higher. You da man Doc!
Long $BLPH and long Dr. KSS!

Add a Topic
5971
Add a Topic
3932
Add a Topic
5971
๐Ÿ‘ 525
linling88
linling88
5 years ago

$TSRO
(#PD-1, #TIM-3, #LAG-3)

TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042
TSR-042 is the first TESARO immuno-oncology candidate to enter a registration program
Ongoing clinical trial expanded to enroll patients with endometrial cancer
Patient-centric administration schedule with every 6 week dosing

WALTHAM, Mass., April 27, 2017 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that following the recent identification of a fixed dose and patient-centric dosing schedule, the ongoing clinical trial of TSR-042 has been expanded to enroll patients with metastatic microsatellite instability high (MSI-H) endometrial cancer who have progressed following one or two prior chemotherapy treatments. During the first 12 weeks of treatment, TSR-042 is administered once every three weeks, followed by a single dose administration every six weeks until disease progression. The intent of this study is to support a request for accelerated approval and Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA). The primary endpoints of this trial are overall response rate (ORR) and duration of response, and secondary endpoints include disease control rate, progression free survival (PFS), and overall survival (OS). The addition of cohorts for patients with other tumor types is also planned. This is the first clinical development program within a broader plan that includes potential label expansion trials of TSR-042 in multiple cancers in combination with ZEJULAยฎ, TSR-022, TESARO’s anti-TIM-3 antibody, and TSR-033, TESARO’s anti-LAG-3 antibody..[…]

http://ir.tesarobio.com/releasedetail.cfm?ReleaseID=1023253

Ownership: back in TSRO after viewing the extremely broad label granted by FDA at the time of niraparib’ approval. Today’s announcement is considered quite significant as endometrial cancer remains a vast, untapped market. Tesaro stock is up >3% over heavy volume.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf

Add a Topic
3397
Add a Topic
3397
Add a Topic
3022
๐Ÿ‘ 7490
petervr
petervr
5 years ago

Found in The Economist.
Quite insightful and interesting.
“How to Have a Better Death”
http://tinyurl.com/mz5kexg

๐Ÿ‘ 1539
jfloyd999
jfloyd999
5 years ago
Reply to  petervr

Thanks, enjoyed that.

๐Ÿ‘ 52
Frenchy
Frenchy
5 years ago

Login on the old fashion way. Great work Doc. Sold a stagnant position, ETF $HACK, for the exact same price I bought it 2 years ago!!!! and bought $NTRP at $14.71 a few min before closing and go figure, I made 3% before the bell rang which is more than I did with HACK in two years…lol!

Newly long $NTRP with a starter position.

Add a Topic
900
๐Ÿ‘ 741
chip12
chip12
5 years ago
Reply to  Frenchy

$NTRP After Hours Yahoo says $17.48 and E Trade says $18.75. No news. Starter Position.

๐Ÿ‘ 436
linling88
linling88
5 years ago
Reply to  chip12

$NTRP

AH trading: I wouldn’t get too excited…just checked the Naz official site and only 100 shares were traded.

Beware of this kind of scam.

๐Ÿ‘ 7490
chip12
chip12
5 years ago
Reply to  linling88

$NTRP Always respect your expert viewpoint. Are you avoiding this binary -would you mind sharing your strategy?

๐Ÿ‘ 436
linling88
linling88
5 years ago
Reply to  chip12

$NTRP:

Hi chip12: I assumed you were addressing the question to me. Thanks for being interested in my i opinion.

Yes, I am going through NTRP’s binary event without hedging. I’ve only acquired a modest position though, being a very recent long.

Add a Topic
6067
๐Ÿ‘ 7490
chip12
chip12
5 years ago
Reply to  linling88

$NTRP
Hi Helen, Yes I am always very interested in your opinions thanks. I am also in for just a small starter because I like the unique method of action, but I realize its a long shot. It could double or more if it has success and lose up to 75% if not.

๐Ÿ‘ 436
prageav1112
prageav1112
5 years ago
Reply to  chip12

$NTRP Hoping for results AM tomorrow. But if its not announced AM, I will trim my position. Just my instinct.

๐Ÿ‘ 47
aladdin
aladdin
5 years ago
Reply to  prageav1112

re:$NTRP
You & everybody else. Your position should be sized for a binary event. If you already did that don’t 2nd guess. If no news premarket then Friday will be the most one-sided preannouncement trading day yet.

๐Ÿ‘ 376
prageav1112
prageav1112
5 years ago
Reply to  aladdin

$NTRP: I have 1/2 pos, will trim it to 1/4. But I really want the drug to work. ALZ patients need some relief.

๐Ÿ‘ 47
traydon
traydon
5 years ago
Reply to  chip12

I got a little fancy: A) bought NTRP and sold the May $30 call and B) also bought the Oct $35 Call. Selling the May $30 Call reduced my downside risk by the price of the call while capping my upside at what would still be more than 100% gain.

Add a Topic
1278
๐Ÿ‘ 732
kucheka
kucheka
5 years ago

#FDA — (Reuters) A U.S. Senate committee voted on Thursday to advance the nomination of Dr. Scott Gottlieb to lead the Food and Drug Administration.

The vote means Gottlieb’s nomination will now be voted on by the full Senate, where he is expected to be confirmed.

Add a Topic
3022
๐Ÿ‘ 452
frankw17
5 years ago
Reply to  kucheka

Long $AKBA:
Akebia Therapeutics Inc (NASDAQ:AKBA) had its price target raised by analysts at HC Wainwright from $18.00 to $21.00. They now have a “buy” rating on the stock. 68.0% upside from the previous close of $12.50.
Akebia Therapeutics Inc (NASDAQ:AKBA) had its price target raised by analysts at Needham & Company LLC from $14.00 to $18.00. They now have a “buy” rating on the stock. 44.0% upside from the previous close of $12.50.
Regards,
Frank

Add a Topic
5971
Add a Topic
1278
Add a Topic
5971
๐Ÿ‘ 1322
mmdwacjm
5 years ago

LONG ONOV CR-10 DISINFECTANT IS APPROVED FOR SALE IN GUATEMALA. Hopefully many more countries to follow, but this company should be on the map now with real sales and hopefully great word of mouth about how miraculous the product is! Mark

๐Ÿ‘ 129
SoGiAm
5 years ago

Cat Escapes Bag: The Elusive Twelfth Biotech of Christmas
PLEASE everyone JOIN the discussion there so all other open threads may be closed per ZKSS request, whom is busy ATM; TIA:
https://www.sgumdev.stockgumshoe.com/2017/04/long-idea-of-the-year/#comments
๐Ÿ™‚ ๐Ÿ™‚ ๐Ÿ™‚ #ZKSS is THE best! YES! ๐Ÿ™‚ ๐Ÿ™‚ ๐Ÿ™‚
๐Ÿ™‚ The Gummune Rocks! ๐Ÿ™‚
๐Ÿ™‚ PLEASE Alwayz use $Tickers in EACH post! ๐Ÿ™‚

๐Ÿ‘ 11466
smanuelm
smanuelm
5 years ago

$notiker edited

๐Ÿ‘ 571
skisun
skisun
5 years ago

Should I keep holding on this one? Down 33%!

petervr
petervr
5 years ago
Reply to  skisun

skisun-
PLEASE Alwayz use $Tickers in EACH post!
I have no idea which company you are referring to.

๐Ÿ‘ 1539
warderwill
warderwill
5 years ago

$SCYX is down 36% today. Was anyone really expecting earnings to be a factor ? What’s the real story?

๐Ÿ‘ 17
cw99
5 years ago
Reply to  warderwill

$SCYX
Bruh, seriously? You been under a rock? First, come over to new thread. Second, start reading new thread from this morning on, you will find out everything you need to know. Basically, hold won’t be lifted until probably early 2018

Add a Topic
5916
๐Ÿ‘ 1235
eemajin
5 years ago
Reply to  cw99

Canโ€™t find a newer thread for $SCYX.

๐Ÿ‘ 264
SoGiAm
5 years ago
Reply to  eemajin

NEWEST articles may always be located by going to the top of the thread and clicking on Dr. KSS’s author’s page: [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics and his words and opinions are his own. You can see all of his past articles and most recent comments at his Stock Gumshoe page.] https://www.sgumdev.stockgumshoe.com/author/dr-kss-md-phd/ Best2You

Add a Topic
3932
Add a Topic
5971
๐Ÿ‘ 11466
JoeS
JoeS
5 years ago
Reply to  eemajin

EEMajin- He means the most recent (current) posts regarding $SCYX will be found on the most recent (current) thread. It is not necessarily devoted to $SCYX, but is where most are posting currently. Cheers.

๐Ÿ‘ 1768
backoffice
5 years ago

So $SCYX, hold, sell,or add?

๐Ÿ‘ 368